Hepatitis C Therapies Perform Well in Challenging Patients

Medscape Coverage from
Digestive Disease Week (DDW) 2017

Hepatitis C Therapies Perform Well in Challenging Patients
William F. Balistreri, MD

At this year's Digestive Disease Week, several studies looked into the nuances of treating hepatitis C virus (HCV)infection. Of particular interest were new data regarding difficult-to-treat groups and the validation of shorter, simpler regimens

Glecaprevir and PibrentasvirIn several phase 2 and 3 clinical trials, patients who received the pangenotypic direct-acting antivirals (DAAs) glecaprevir (GLE) and pibrentasvir (PIB) achieved sustained virologic response (SVR) rates of 92%-100% across all six major HCV genotypes...

Sofosbuvir/Velpatasvir/Voxilaprevir
A pangenotypic combination of sofosbuvir (SOF), velpatasvir (VEL), and voxilaprevir (VOX) was designed to inhibit three distinct HCV targets: the NS5B polymerase, the NS5A protein, and NS3/4A protease, respectively.

Flamm and colleagues^[3] presented cumulative data from 1056 patients with and without compensated cirrhosis who were infected with HCV genotype 1-6 and treated with the once-daily fixed-dose combination tablet of SOF/VEL/VOX in phase 3 studies....

Continue reading....

Free registration required